Abstract: Somatostatin receptor 2 (SSTR2) is a class of G protein-coupled receptor that are highly expressed in a variety of tumors. Imaging examination with SSTR2 as the target can effectively diagnose the location and metastasis of the tumor and evaluate the degree of malignancy, treatment efficacy and prognosis of the tumor, which has a good clinical application prospect. ⁶⁸Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-Tyr(3)-octreotide (DOTATOC) is a radiodiagnostic drug that can be used for PET localization of a variety of malignant tumors by binding to SSTR2 with high affinity. The authors sort out the drug information, development history and mechanism of action of ⁶⁸Ga-DOTATOC, and review the application progress of ⁶⁸Ga-DOTATOC in neuroendocrine neoplasms (NEN) and non NEN, and the future development prospects of ⁶⁸Ga-DOTATOC was prospected.